To assess the safety and acceptance of the PrePex device for medical male circumcision (MMC) in rural Uganda.
In an observational study, HIV-uninfected, uncircumcised men aged 18 and older who requested elective MMC were informed about the PrePex and dorsal slit methods and offered a free choice of their preferred procedure. 100 men received PrePex to assess preliminary safety (aim 1). An additional 329 men, 250 chose PrePex and 79 chose Dorsal slit, were enrolled following approval by the Safety Monitoring Committee (aim 2). Men were followed up at 7 days to assess adverse events (AEs) and to remove the PrePex device. Wound healing was assessed at 4 weeks, with subsequent weekly follow up until completed healing.
The PrePex device was contraindicated in 5.7% of men due to a tight prepuce or phimosis/adhesions. Among 429 enrolled men 350 (82.0%) got the PrePex device and 79 (18.0%) the dorsal slit procedure. 250 of 329 men (76.0%) who were invited to choose between the 2 procedures chose Prepex. There were 9 AEs (2.6%) with the PrePex, of which 5 (1.4%) were severe complications, 4 due to patient self-removal of the device leading to edema and urinary obstruction requiring emergency surgical circumcision, and one due to wound dehiscence following device removal. 71.8% of men reported an unpleasant odor prior to PrePex removal. Cumulative rates of completed wound healing with the PrePex were 56.7% at week 4, 84.8% week 5, 97.6% week 6 and 98.6% week 7, compared to 98.7% at week 4 with dorsal slit (p<0.0001).
The PrePex device was well accepted, but healing was slower than with dorsal slit surgery. Severe complications, primarily following PrePex self-removal, required rapid access to emergency surgical facilities. The need to return for removal and delayed healing may increase Program cost and client burden.
Citation: Kigozi G, Musoke R, Watya S, Kighoma N, Nkale J, Nakafeero M, et al. (2014) The Safety and Acceptance of the PrePex Device for Non-Surgical Adult Male Circumcision in Rakai, Uganda. A Non-Randomized Observational Study. PLoS ONE 9(8): e100008. doi:10.1371/journal.pone.0100008
Editor: Alex Welte, University of the Stellenbosch, South Africa
Received: January 14, 2014; Accepted: May 21, 2014; Published: August 21, 2014
Copyright: © 2014 Kigozi et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This study was supported by grant UO1 AI075115-0451 from the Division of AIDS (DAIDS) of the US National Institutes of Health (NIH). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing interests: Ronald H. Gray is a member of the PLOS ONE editorial board. This does not alter the authors' adherence to PLOS ONE Editorial policies and criteria.
Medical male circumcision (MMC) reduces male HIV acquisition by 50–60% – and has been recommended by UNAIDS/WHO as a component of HIV prevention . However, progress with scale up of MMC services in 14 priority countries in sub-Saharan Africa has been suboptimal , and there is a need to improve access to and the efficiency of MMC services. One obstacle to MMC scale up in adolescents and adults is the time and provider skills required for conventional surgical procedures (forceps guided, dorsal slit and sleeve circumcision) all of which entail a surgical time of 15–45 minutes (depending on provider experience), aseptic conditions and skill in hemostasis and suturing for wound closure. Two devices, the Shang Ring  and the PrePex device – offer potential advantages in reduction of procedure time which could increase throughput of clients, a lower requirement for asepsis and the procedures can be performed by less skilled providers , ,  which could facilitate task shifting and sharing. Both devices must be removed 5–9 days after placement.
The Shang Ring requires injectable local anesthesia and primary surgical removal of the foreskin, and the procedure takes ~5 minutes . We previously reported findings on the safety and acceptability of this MMC method  The PrePex device is applied under topical anesthesia because the foreskin remains intact and is compressed by radial elastic pressure leading to distal necrosis thus shortening procedure time. The method requires secondary removal of necrotic skin at 5–9 days post-placement. Published studies of the PrePex device in Rwanda suggest that the time required for placement is ~3 minutes –, that lower cadre personnel such as nurses can safely place the device , and that adverse events are infrequent. The World Health Organization Technical Advisory Group (WHO TAG) reviewed eight published and unpublished studies of the PrePex device in January, 2013, and concluded that in ~7% of clients the PrePex device could not be used because a tight foreskin precluded placement, that adverse events were ~1.7% and that severe adverse events, mainly due to displacement or self-removal of the elastic ring, required urgent surgical intervention in 0.4% of cases . The WHO TAG provided prequalification for use of the PrePex in men aged 18 or older, but recommended that skilled surgical back up was available to manage severe complications 
We conducted a safety and acceptability study of the PrePex device in rural Rakai District of southwestern Uganda.
The study was reviewed and approved by Institutional Review Boards in Uganda (the Scientific and Ethics Committee of the Uganda Virus Research Institute and the Uganda National Council for Science and Technology), and the U.S.A. (the Johns Hopkins University, Bloomberg School of Public Health Institutional Review Board). Permission to import the PrePex device for research was provided by the Uganda National Drug Authority, and the study was monitored by a Safety Monitoring Committee (SMC.) Under the study protocol, enrollment was paused after the first 50 and 100 PrePex device placements and findings were reviewed by the SMC prior to continuation of enrollment.
This implementation research study was designed and conducted as an observational study between November 2012 and June 2013 in Rakai district, Uganda. Participant enrollment was done between November 2012 and May 2013. The last follow-up visit was conducted in June 2013. Men, who requested free MMC services from the Rakai Health Sciences Program (RHSP), were informed about the dorsal slit and PrePex methods of circumcision, and offered free HIV Counseling and Testing (HCT). Uncircumcised HIV-negative men aged 18 years and older were invited to enroll in the study and asked to provide written informed consent. One hundred (100) men were enrolled and PrePex placed to assess preliminary safety of the PrePex device (aim 1). The safety monitoring committee approved continuation of enrolment (aim 2) to enable assessment of safety and acceptability of PrePex. The consent form explained the nature of the two MMC procedures, known risks and benefits, and their ability to select their procedure of choice. Consenting men were provided with further detailed information and asked to nominate their preferred method of MMC and to give reasons for their preference. All men were screened for contraindications to their method of choice. Men with symptoms or signs of genitourinary infection (discharge, ulceration or dysuria) were treated and MMC was deferred until the problem was resolved. Men with anatomic abnormalities were referred for assessment by the consultant urologists (SW and DN).
MMC was performed by trained clinical officers (equivalent to a physician's assistant) and registered nurses. The dorsal slit was performed as described in the WHO manual for male circumcision under local anesthesia 13 The PrePex device was placed according to the manufacturer's instructions (Circ MedTech Ltd, Israel.) The diameter of the penis at the coronal sulcus was determined using the manufacturer's sizing device and an appropriately sized device was selected. Lignocaine 5% gel prepared by a Rwanda team of instructors, was applied to the inner surface of the foreskin and the firm inner ring inserted at the level of the coronal sulcus. The elastic O-ring was then applied to the external surface of the foreskin using a placement device, to compress the foreskin hence blocking blood flow to the distal preputial tissue. Participants were observed for a minimum of one hour post-placement and pain was assessed using a visual analogue scale (VAS). Men were provided with acetaminophen to alleviate any post-placement pain. Men were then followed up seven days post-placement and the ring and necrotic foreskin were removed per manufacturer's instructions. Pain control during removal used a 10% Cetacaine spray which was applied between the residual necrotic prepuce and the coronal sulcus. Pain during or after removal was assessed by the VAS. Active follow up was used to trace men who failed to come for the scheduled device removal visit.
Participants were then followed up at 4 weeks post-device placement to assess wound healing. Complete wound healing was defined as an intact scar with no scab formation. Men with incomplete wound healing were followed up at weekly intervals until complete wound healing was certified. Unscheduled visits could occur at any time in case of adverse events or other concerns, and participants could contact the Program using a cell phone hot line.
Interviews were conducted at enrollment to ascertain sociodemographic characteristics and sexual behaviors. At each follow up visit, interviews were conducted using standard questionnaires to determine symptoms suggestive of adverse events (AEs), resumption of intercourse, condom use and sexual satisfaction/dysfunction among those who had resumed intercourse. Pain was assessed using a VAS, and pain scores of 7 or above lasting more than 2 minutes were classified as adverse events. PrePex recipients were also asked about post-placement odor from the necrotic foreskin and whether this interfered with their normal activities of daily living.
Adverse events (AEs) were predefined based on classification provided by the manufacturer and the Rwandan Team. Severity was graded as mild if no treatment was needed, moderate if non-surgical treatment was indicated, and severe if surgical intervention or hospitalization was required. Definitions of AEs can be provided on request.
We present results from the PrePex training phase in which 136 devices were provided by trainees and during the research phase of the study when 350 PrePex devices and 79 dorsal slit MMCs were provided. For the latter phase, we tabulated the number of men who declined to enroll and reasons for non-enrollment, including contraindications to use of the device. The sociodemographic and behavioral characteristics at enrollment were compared between those choosing the PrePex or dorsal slit methods using chi-square tests. Follow up at scheduled visits, severity of pain at placement and removal, experience of unpleasant odor with the PrePex, occurrence of adverse events and the proportions with completed wound healing at 4–7 weeks post-MMC were assessed. A two sample test of proportions was used to compare the proportion with completed wound healing between those who received the PrePex versus those circumcised using the dorsal slit method.
We present the results separately for the training phase and for the main study.
Training in PrePex placement and removal was conducted and certified by PrePex Product Specialists from Rwanda (Dr.Ngeruka M. Leon, Dr.Sibomana Alphouse, Amuhinde Jacpus and Lior Levert) following the manufacturer's guidelines. Seven personnel were trained, and each conducted an average of 13 PrePex circumcisions. There were 136 device placements during training, and 135 (99.3%) of men were followed up at 7 days for device removal. Post-placement pain was minor, but some discomfort (e.g. some mild pain on movement) while wearing the device during the first week was reported by 26.7% of men. There were 9 mild adverse events (6.7%), eight (5.9%) were due to pain with a VAS score ≥7 at time of device removal, and one was due to self-removal of the device because of parental instruction. The removal of the device was without complications and dorsal slit surgery was provided as a service. An unpleasant odor was reported by 77.8% of men, and 30.5% said this interfered with their daily activities.
Follow up at 4 weeks was completed by 122 men (89.7%), and complete wound healing was certified in 49.2%. Cumulative wound healing was 90.2% at week 5, 98.9% at week 6, and 100% by the 7th week.
One hundred (100) men were enrolled in the preliminary safety stage (aim 1) and all got PrePex. There were 592 potentially eligible men for aim 2 of whom 329 (55.6%) were enrolled into the study; 250 (76.0%) chose the PrePex device and 79 (24.0%) selected the dorsal slit procedure (Figure 1). Among the 263 men who did not enroll, the predominant reasons for non-enrollment were inability to adhere to the follow up schedule (56.7%), lack of interest in the study (25.9%) and protocol determined pauses of enrollment (7.6%). Contraindications to placement of the PrePex device were found in 17 participants (6.5%) and included narrowing of preputial opening (5.7%) due to severe phimosis, tight foreskin and adhesions.
The characteristics and behaviors at enrollment were similar among those choosing the PrePex or dorsal slit (Table 1), and the majority of participants were young men aged between 18–24 years. Among PrePex recipients, the predominant device sizes were B (28.6%), C (34.8%) and D (18.0%). Pain after Prepex placement was mild and was reported by 2.9% of men at 30 minutes, 4.9% at one hour and 2.3% at two hours post-device placement.
Follow up at 7 days was completed by 97.7% of PrePex recipients (342/350) and 86.1% of dorsal slit recipients (68/79). Among the 342 PrePex clients seen at day 7, 14.3% (49) reported some discomfort over the preceding week. Virtually all men reported some pain at time of device removal but none reported severe pain scored ≥7 on the VAS. An unpleasant smell during the first week after PrePex placement was reported by 71.8% of men, 8.6% said this odor affected activities of daily living and 10.2% said the odor was noticed by other people in the vicinity. Follow up for the scheduled 4 week visit was 93.1% (326/350) among PrePex and 94.9% (75/79) among dorsal slit recipients. Wound healing was certified as complete in 56.7% (185/326) PrePex and 98.7% (74/75) dorsal slit circumcisions (p<0.0001). The cumulative rates of completed wound healing with the PrePex device were 84.8% at week 5, 97.6% at week 6 and 98.6% at week 7.
Adverse events with the PrePex device are tabulated in Table 2. There were a total of 9 adverse events (2.6%), 4 were mild events (1.1%) and five were severe adverse events (1.4%) which are summarized in Table 3, and selected severe adverse events are shown in Figure 2 a–d with written consent of participants. Among the mild AEs, two participants removed the device without complications and did not request surgical circumcision as a service, one had device displacement and one had edema distal to the circumcision scar Four severe events were due to premature non-medical removal of the device and in 3 cases the participant removed the device because of edema, pain, or difficulty voiding. All 4 SAEs required sleeve circumcision and all subsequently resolved. One participant had the device removed on the 7th day without complications, but subsequently experienced wound dehiscence requiring surgical repair. It is noteworthy that 7 participants (2.0%) removed the device themselves, and four experienced serious complications (1.1%). No AEs were observed among 79 dorsal slit recipients.
Figure 2a, device self removal with edema and superficial ulceration on day 2 post placement. Figure 2b, device self removal with edema on day 1 post placement. Figure 2C, wound dehiscence on day 17 post device placement. Figure 2d, self removal of the device with edema and necrosis on day 9.
The mean time for device placement was 4.5 minutes (range 2–18 minutes), and the mean time required for removal was 4.3 minutes (range2–14) minutes. The mean time required for dorsal slit was 14.9 minutes (range 8–35 minutes).
The PrePex device was well accepted among study participants in this rural Ugandan population, and 76.0% (250/329) selected the PrePex device rather than dorsal slit surgery when offered a free choice of MMC method. It should however be noted that 263 (44.4%) eligible men were not enrolled in the study for various reasons the commonest being reluctance or inability to adhere to the study follow-up schedule or lack of interest in the study (figure 1). These opted for circumcision using the dorsal slit method via the routine MMC service program. This suggests that if PrePex is introduced in this population only ~42.2% (250/592) men would receive circumcision using Prepex.
The time required for placement and removal of the device was substantially shorter than dorsal slit surgery, but there is need for a mandatory day 7 visit for device removal. The time for complete wound healing was slower with the PrePex than conventional surgery, as has been found in other studies. The need for a mandatory day 7 visit for device removal and need for additional follow up due to a longer healing time burdens the clients and increases the costs associated with PrePex.
The observed rate of moderate/severe adverse events (1.4%) was similar to that reported in other PrePex studies , , , and comparable to rates with the Shang Ring device (1.0%) and dorsal slit surgery (0.8%) in this population  However, we observed 7 cases of participant self-removal of the PrePex device (2.0%), and 4 of these cases resulted in severe complications requiring immediate surgery. One Rwandan study observed two cases of self-removal in 518 PrePex procedures (0.4%)  but another Rwandan study of 144 PrePex recipients reported no cases  Unpleasant smell was reported by 71.8% of clients with 10.2% reporting that the odor was noticed by people in their vicinity. This calls for measures to prevent or minimize the offensive odor since it can affect both clients and providers.
We have conducted two studies of MMC devices in Rakai, Uganda which allow comparison between the Shang Ring and PrePex devices in a single setting. A randomized trial was not possible because the manufacture was reluctant to sell the PrePex device for a comparative trial of the PrePex and Shang Ring. Therefore, we can not directly asses the relative advantages and disadvantages of the two devices. The Shang Ring requires local anesthesia injection and greater attention to asepsis because the foreskin is surgically removed, whereas the PrePex requires only topical anesthesia and the need for asepsis is less because there is no open surgical wound. We observed no severe adverse events with 500 Shang Ring procedures  and the WHO TAG reported none among 1,983 procedures , whereas we found a rate of 1.4% severe adverse events which required emergency surgery among 350 PrePex procedures. Thus, the risk of severe adverse events with the PrePex, mainly attributable to self-removal of the device, constitutes a potential disadvantage. An analogy can be made to a randomized trial of neonatal circumcision in Botswana in which rare but severe adverse events due to displacement of the Plastibell device led the authors to conclude that this method was less suitable for settings where emergency care is unavailable .
Circumcision devices such as the PrePex or Shang Ring have the potential to increase the efficiency of circumcision programs in Africa by faster procedure times allowing greater throughput of clients, lower surgical skill requirements and the potential for task shifting to less highly skilled health personnel such as nurses. The cost-effectiveness of these devices is still unknown ,  since prices for large scale programs have not been finalized. The manufacturer's cost per PrePex device for this study was USD $20.00, but does not include the costs of personnel, other accessories and facilities which are unavailable at time of writing.
Limitations to this study include the fact that this was observational and not a randomized trial, nevertheless findings are consistent with those from other studies. Another potential limitation is that participants who accepted study enrolment could have been self selected with those interested in PrePex being more likely to enroll. This can potentially lead to over estimation of the acceptance of the PrePex device.
In summary, we found that the PrePex device was well accepted in this rural Ugandan population but healing was slower than with conventional surgery, recipients reported an unpleasant odor during the first week, and patient self-removal of the device that can lead to serious complications necessitating emergency surgical intervention was a concern. These results support the WHO TAG  recommendations that, while the PrePex device is efficacious and safe in men 18 years and older, clients need to be instructed not to remove the device themselves, clients and providers should be trained to recognize severe complications, and surgical facilities should be available or accessible within 6–12 hours in order to manage these complications. It would be an advantage if the device design could incorporate safe guards against self-removal.
This study was supported by grant UO1 AI075115-0451 from the Division of AIDS (DAIDS) of the US National Institutes of Health (NIH). We acknowledge the assistance of the Rwandan Training team (Dr.Ngeruka M. Leon, Dr.Sibomana Alphouse, Amuhinde Jacpus and Lior Levert) and Margaret Nagujja from IHK and express our gratitude to the study participants and Rakai Health Sciences Program staff.
Conceived and designed the experiments: RHG GK MJW RM SW DS NS. Performed the experiments: GK NK JN SW DN MN FN. Analyzed the data: RM GK MN RHG JN. Wrote the paper: GK RHG RM MJW FN DS NS SW DN NK JN MN.
- 1. Auvert B, Taljaard D, Lagarde E, Sobngwi-Tambekou J, Sitta R, et al. (2005) Randomized, controlled intervention trial of male circumcision for reduction of HIV infection risk: the ANRS 1265 Trial. PLoS medicine 2(11): e298. doi: 10.1371/journal.pmed.0020298
- 2. Bailey RC, Moses S, Parker CB, Agot K, Maclean I, et al. (2007) Male circumcision for HIV prevention in young men in Kisumu, Kenya: a randomised controlled trial. Lancet 369(9562): 643–56. doi: 10.1016/s0140-6736(07)60312-2
- 3. Gray RH, Kigozi G, Serwadda D, Makumbi F, Watya S, et al. (2007) Male circumcision for HIV prevention in men in Rakai, Uganda: a randomised trial. Lancet 369(9562): 657–66. doi: 10.1016/s0140-6736(07)60313-4
- 4. UNAIDS (2007) New data on male circumcision and HIV prevention: policy and programme implications. Montreux doi: 10.1016/s0968-8080(07)29307-3
- 5. UNAIDS/WHO/SACEMA (2010) Progress in male circumcision scale-up: country implementation and research update. Geneva: WHO.
- 6. Masson P, Li PS, Barone MA, Goldstein M (2010) The ShangRing device for simplified adult circumcision. Nat Rev Urol 7(11): 638–42. doi: 10.1038/nrurol.2010.167
- 7. Mutabazi V, Kaplan SA, Rwamasirabo E, Bitega JP, Ngeruka ML, et al. (2013) One-Arm, Open-Label, Prospective, Cohort Field Study to Assess the Safety and Efficacy of the PrePex Device for Scale-Up of Nonsurgical Circumcision When Performed by Nurses in Resource-Limited Settings for HIV Prevention. Journal of acquired immune deficiency syndromes (1999) 63(3): 315–22. doi: 10.1097/qai.0b013e31828e6412
- 8. Bitega JP, Ngeruka ML, Hategekimana T, Asiimwe A, Binagwaho A (2011) Safety and efficacy of the PrePex device for rapid scale-up of male circumcision for HIV prevention in resource-limited settings. Journal of acquired immune deficiency syndromes (1999) 58(5): e127–34. doi: 10.1097/qai.0b013e3182354e65
- 9. Mutabazi V, Kaplan SA, Rwamasirabo E, Bitega JP, Ngeruka ML, et al. (2012) HIV prevention: male circumcision comparison between a nonsurgical device to a surgical technique in resource-limited settings: a prospective, randomized, nonmasked trial. Journal of acquired immune deficiency syndromes (1999) 61(1): 49–55. doi: 10.1097/qai.0b013e3182631d69
- 10. McIntyre JA (2011) Can devices for adult male circumcision help bridge the implementation gap for HIV prevention services? Journal of acquired immune deficiency syndromes (1999) 58(5): 506–8. doi: 10.1097/qai.0b013e318237af5d
- 11. Kigozi G, Musoke R, Watya S, Kighoma N, Ssebbowa P, et al. (2013) The Acceptability and Safety of the Shang Ring for Adult Male Circumcision in Rakai, Uganda. Journal of acquired immune deficiency syndromes (1999). 15;63(5): 617–21. doi: 10.1097/qai.0b013e3182968dda
- 12. WHO (2013) WHO Technical Advisory Group on Innovations in Male Circumcision; Evaluation of two adult devices. Geneva: WHO
- 13. Duffy K, Galukande M, Wooding N, Dea M, Coutinho A (2013) Reach and Cost-Effectiveness of the PrePex Device for Safe Male Circumcision in Uganda. PLoS One 8(5): e63134. doi: 10.1371/journal.pone.0063134
- 14. Plank RM, Ndubuka NO, Wirth KE, Mwambona JT, Kebaabetswe P, et al. (2013) A randomized trial of Mogen clamp versus Plastibell for neonatal male circumcision in Botswana. Journal of acquired immune deficiency syndromes (1999) 62(5): e131–7. doi: 10.1097/qai.0b013e318285d449
- 15. Obiero W, Young MR, Bailey RC (2013) The PrePex device is unlikely to achieve cost-savings compared to the forceps-guided method in male circumcision programs in sub-Saharan Africa. PLoS One 8(1): e53380. doi: 10.1371/journal.pone.0053380